<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402178</url>
  </required_header>
  <id_info>
    <org_study_id>E2082-J081-001</org_study_id>
    <nct_id>NCT03402178</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Studies to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the safety, tolerability, and pharmacokinetics (PK)
      of single ascending oral doses of E2082 in healthy Japanese adult and elderly male
      participants, and to evaluate the safety, tolerability, and PK of multiple ascending oral
      doses of E2082 in healthy Japanese and Caucasian adult male participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Mean value of the maximum observed concentration (Cmax) of E2082 under a fasted state for the single ascending dose (SAD) Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.</time_frame>
    <description>Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of Cmax of E2082 under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose</time_frame>
    <description>Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of the time at which the highest plasma concentration (Tmax) of E2082 occurs under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.</time_frame>
    <description>Tmax is the time at which the highest concentration of E2082 occurs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of Tmax of E2082 under fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose</time_frame>
    <description>Tmax is the time at which the highest concentration of E2082 occurs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of the area under the concentration-time curve from zero time to 24 hours after dosing (AUC[0-24h]) under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC(0-24h) under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC from zero time to the time of the last quantifiable concentration (AUC[0-t]) under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.</time_frame>
    <description>AUC(0-t) represents the total drug exposure from zero time to the time of the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC(0-t) under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose</time_frame>
    <description>AUC(0-t) represents the total drug exposure from zero time to the time of the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC from zero time to 72 hours after dosing (AUC[0-72h]) under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
    <description>AUC(0-72h) represents the total drug exposure from zero time to 72 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC(0-72h) under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
    <description>AUC(0-72h) represents the total drug exposure from zero time to 72 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC from zero time to 96 hours after dosing (AUC[0-96h]) under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours postdose</time_frame>
    <description>AUC(0-96h) represents the total drug exposure from zero time to 96 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC(0-96h) under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours postdose</time_frame>
    <description>AUC(0-96h) represents the total drug exposure from zero time to 96 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC from zero time extrapolated to infinite time (AUC[0-inf]) under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.</time_frame>
    <description>AUC(0-inf) represents the total drug exposure from zero time extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of AUC(0-inf) under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose</time_frame>
    <description>AUC(0-inf) represents the total drug exposure from zero time extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of terminal elimination phase half-life (t½) of E2082 under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.</time_frame>
    <description>t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of t½ of E2082 under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose</time_frame>
    <description>t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of apparent total clearance (CL/F) of E2082 under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), and 168 (Day 8) hours postdose for all cohorts. Additionally, 240 (Day 11) and 336 (Day 15) hours postdose for Cohort 4 or later.</time_frame>
    <description>CL/F is the apparent total clearance following extravascular (example, oral) administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of CL/F of E2082 under a fasted state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 168 (Day 8), 240 (Day 11), and 336 (Day 15) hours postdose</time_frame>
    <description>CL/F is the apparent total clearance following extravascular (example, oral) administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of the apparent volume of distribution at terminal phase of E2082 on Day 1 (Vz/F) under a fasted state for the SAD Cohorts 1-10</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The apparent volume of distribution gives information about the amount of drug distributed in body tissue rather than the plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Mean value of Vz/F of E2082 on Day 1 under a fed state for the SAD Cohort 5</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose</time_frame>
    <description>The apparent volume of distribution gives information about the amount of drug distributed in body tissue rather than the plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of Cmax of E2082 for the multiple ascending dose (MAD) cohorts on Day 1</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose of Day 1</time_frame>
    <description>Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of Cmax of E2082 at steady state (Css,max) for the MAD cohorts on Day 14</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose of Day 14</time_frame>
    <description>Cmax is the maximum observed concentration of E2082 in the plasma that is measured after a dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of the minimum observed concentration (Cmin) of E2082 for the MAD cohorts on Day 1</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose of Day 1</time_frame>
    <description>Cmin is the minimum observed concentration of E2082 in the plasma that is measured after a dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of Cmin of E2082 at steady state (Css,min) for the MAD cohorts</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 14</time_frame>
    <description>Css,min is the minimum observed concentration of E2082 in the plasma that is measured after a dose at steady state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of Tmax of E2082 for the MAD cohorts on Day 1</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose of Day 1</time_frame>
    <description>Tmax is the time at which the highest concentration of E2082 occurs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of Tmax of E2082 at steady state (Tss,max) for the MAD cohorts</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 14</time_frame>
    <description>Tss,max is the time at which the highest concentration of E2082 occurs at steady state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of the average steady state concentration (Css,av) of E2082 for the MAD cohorts</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 14</time_frame>
    <description>The average steady state concentration is calculated as AUC(0-τ)/τ. τ is the dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of AUC(0-24h) after dosing on Day 1 for the MAD cohorts</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours postdose of Day 1</time_frame>
    <description>AUC(0-24h) represents the total drug exposure from zero time to 24 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of AUC(0-τ) for the MAD cohorts</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 14</time_frame>
    <description>AUC(0-τ) is AUC over the dosing interval on multiple dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of t½ following the last day of dosing for the MAD cohorts</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 14</time_frame>
    <description>t½ is the time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Peak-trough fluctuation (PTF) for the MAD cohorts</measure>
    <time_frame>Predose at Days 1, 2, 6, 10, 12, 13, and 14. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 14.</time_frame>
    <description>PTF is peak to trough fluctuation at steady-state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Accumulation ratio for AUC and Cmax (Rac) for the MAD cohorts</measure>
    <time_frame>Predose at Days 1, 2, 6, 10, 12, 13, and 14. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose of Day 1. 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 168, 240, and 336 hours postdose of Day 14.</time_frame>
    <description>Rac (Cmax) is calculated as the ratio of drug concentrations observed during a dosing interval at steady-state divided by drug concentrations seen during the dosing interval after a single (first) dose. Rac (AUC)=steady state AUC(0-τ)/single dose AUC(0- τ), where τ is dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of apparent total clearance at steady state (CLss/F) for the MAD cohorts on Day 14</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and up to 336 hours postdose of Day 14</time_frame>
    <description>CLss/F is the apparent total clearance at steady state following extravascular (example, oral) administration. It is defined as the rate of drug elimination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean value of Vz/F for the MAD cohorts on Day 14</measure>
    <time_frame>Predose and 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and up to 336 hours postdose of Day 14</time_frame>
    <description>Vz/F is apparent volume of distribution at terminal phase on Day 14.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>E2082</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2082 will be administered as a 0.2 milligram (mg) solution, a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, and 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg, 15 mg, 25 mg, 40 mg, and 10 mg E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 3, respectively, will receive 2.5 mg, 5 mg, and 10 mg tablets once daily for 14 days. E2082 will be administered under fasted conditions on Day 1 and Day 14 and under fed conditions during Day 2 to Day 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2082-matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo will be administered as a 0.2 mg solution, a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, and 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg, 15 mg, 25 mg, 40 mg, and 10 mg matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 3, respectively, will receive 2.5 mg, 5 mg, and 10 mg matched placebo tablets once daily for 14 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 14 and under fed conditions during Day 2 to Day 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2082</intervention_name>
    <description>solution or tablet</description>
    <arm_group_label>E2082</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution or tablet matched to E2082</description>
    <arm_group_label>E2082-matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the following criteria to be included in this study:

          -  Non-smoking, age ≥20 years and &lt;55 years old adult male (Cohorts 1 to 9 of Part A and
             all cohorts of Part B), or age ≥55 years and ≤85 years old elderly male (only Cohort
             10 of Part A) at the time of informed consent. To be considered non-smokers,
             participants must have discontinued smoking for at least 4 weeks before dosing.

          -  Body mass index ≥18 and &lt;30 kilograms per meters squared at Screening

        Exclusion Criteria:

        Participants who meet any of the following criteria will be excluded from this study:

          -  Evidence of disease that may influence the outcome of the study within 4 weeks before
             dosing; example, psychiatric disorders and disorders of the gastrointestinal tract,
             liver, kidney, respiratory system, endocrine system, hematological system,
             neurological system, or cardiovascular system, or participants who have a congenital
             abnormality in metabolism

          -  Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of
             E2082, example, hepatectomy, nephrectomy, and digestive organ resection

          -  Any clinically abnormal symptom or organ impairment found by medical history, physical
             examinations, vital signs, electrocardiogram finding, or laboratory test results that
             require medical treatment at Screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>1-888-274-2378</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial Site</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E2082</keyword>
  <keyword>male</keyword>
  <keyword>single ascending dose</keyword>
  <keyword>multiple ascending dose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

